Imipramine Pamoate

Nocturnal Enuresis (bedwetting), Bulimia Nervosa, Panic Disorder + 3 more

Treatment

20 Active Studies for Imipramine Pamoate

What is Imipramine Pamoate

Imipramine

The Generic name of this drug

Treatment Summary

Imipramine is a tricyclic antidepressant (TCA) used to treat depression. It works by blocking the reuptake of serotonin and norepinephrine, two neurotransmitters that regulate mood. It also blocks certain receptors in the body, which can lead to side effects such as sedation, low blood pressure, and blurred vision. Imipramine is also sometimes prescribed to treat conditions such as chronic pain, panic disorder, ADHD, and PTSD.

Tofranil

is the brand name

image of different drug pills on a surface

Imipramine Pamoate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Tofranil

Imipramine

1959

103

Effectiveness

How Imipramine Pamoate Affects Patients

Imipramine is a type of antidepressant that helps to treat depression by increasing the levels of serotonin and norepinephrine, two chemicals in the brain that can affect mood. It is similar to other drugs such as amitriptyline and doxepin. When taken, imipramine can lead to changes in the brain such as increased production of nerve cells and reduced stress responses. It is believed that these changes, along with its effect on serotonin, are what make it an effective antidepressant. Additionally, it may cause a decrease in certain receptors in the brain that help to regulate adrenaline.

How Imipramine Pamoate works in the body

Imipramine helps treat depression by blocking the removal of two important neurotransmitters, norepinephrine and serotonin, from the spaces between neurons. This allows these two chemicals to stay in the spaces between neurons longer, stimulating the neurons and relieving symptoms of depression.

When to interrupt dosage

The recommended dosage of Imipramine Pamoate is contingent upon the diagnosed condition, such as Bedwetting, Bulimia Nervosa and Depression. The amount of dosage is dependent on the mode of administration (e.g. Tablet, sugar coated or Tablet, sugar coated - Oral), as indicated in the below table.

Condition

Dosage

Administration

Bulimia Nervosa

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated - Oral, Tablet, film coated, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet, sugar coated, Tablet, sugar coated - Oral

Nocturnal Enuresis (bedwetting)

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated - Oral, Tablet, film coated, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet, sugar coated, Tablet, sugar coated - Oral

Panic Disorder

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated - Oral, Tablet, film coated, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet, sugar coated, Tablet, sugar coated - Oral

Neuropathic Pain

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated - Oral, Tablet, film coated, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet, sugar coated, Tablet, sugar coated - Oral

Depression

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated - Oral, Tablet, film coated, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet, sugar coated, Tablet, sugar coated - Oral

Attention Deficit Hyperactivity Disorder

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated - Oral, Tablet, film coated, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Tablet, sugar coated, Tablet, sugar coated - Oral

Warnings

Imipramine Pamoate has two contraindications and should not be concomitantly administered when afflicted with any of the conditions in the table below.

Imipramine Pamoate Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Myocardial Infarction

Do Not Combine

There are 20 known major drug interactions with Imipramine Pamoate.

Common Imipramine Pamoate Drug Interactions

Drug Name

Risk Level

Description

Acepromazine

Major

Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Imipramine is combined with Aclidinium.

Alfuzosin

Major

Imipramine may increase the hypotensive activities of Alfuzosin.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Imipramine.

Amoxapine

Major

Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Amoxapine.

Imipramine Pamoate Toxicity & Overdose Risk

Taking too much imipramine can cause dryness in the mouth and eyes, increased body temperature, constipation, difficulty urinating, tiredness, agitation, nightmares, confusion, decreased appetite, stomach pain, vomiting, and a strange taste in the mouth. In rare cases, it can lead to low blood cell counts and blood clotting problems. Infants born to mothers taking imipramine may experience heart problems, fussiness, breathing difficulty, muscle spasms, convulsions, and difficulty urinating. Taking it with other drugs that increase serotonin levels can cause serotonin syndrome. The LD50 for rats is 250mg/

image of a doctor in a lab doing drug, clinical research

Imipramine Pamoate Novel Uses: Which Conditions Have a Clinical Trial Featuring Imipramine Pamoate?

779 active clinical trials are currently assessing the potential of Imipramine Pamoate to provide relief from Attention Deficit Hyperactivity Disorder, Bulimia Nervosa and Depression.

Condition

Clinical Trials

Trial Phases

Attention Deficit Hyperactivity Disorder

60 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 2, Phase 3

Nocturnal Enuresis (bedwetting)

2 Actively Recruiting

Not Applicable

Depression

299 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Bulimia Nervosa

0 Actively Recruiting

Panic Disorder

11 Actively Recruiting

Not Applicable

Neuropathic Pain

4 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Imipramine Pamoate Reviews: What are patients saying about Imipramine Pamoate?

4.3

Patient Review

1/16/2014

Imipramine Pamoate for Depression

Imipramine has been extremely effective for me in treating my psychiatric problems. I've been taking it for most of my life, and the imipramine pamoate formulation seems to really help with side effects like tremor and dry mouth. The old tricyclic antidepressants have a similar effect to the newer SNRIs but are much cheaper, so Imipramine is a great option.

4.3

Patient Review

11/19/2013

Imipramine Pamoate for Depression

The side effects of this medication were really terrible and it made my symptoms worse. I was stressed, agitated, and felt strung-out all the time. I took it for off-label use for ADHD and it is by far the worst medication I have ever taken.

2

Patient Review

1/6/2011

Imipramine Pamoate for Depression

I took this medication for its side effect of causing sleep.

1

Patient Review

7/1/2013

Imipramine Pamoate for Attention Deficit Disorder with Hyperactivity

Imipramine has helped me a lot with my incontinence issues.

Patient Q&A Section about imipramine pamoate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What class of drug is imipramine pamoate?

"Imipramine belongs to a class of antidepressants known as tricyclics. It treats depression by increasing the levels of certain chemicals in the brain that are necessary for mental balance."

Answered by AI

What is imipramine pamoate used for?

"This drug is given to people who are suffering from depression. It is thought to work by aiding in the regulation of moods, and may also help with sleep and appetite. It may also give the patient more energy to take part in daily activities. The drug imipramine pamoate is classified as a tricyclic antidepressant."

Answered by AI

What is the difference between Imipramine HCl and pamoate?

"Imipramine HCl is FDA approved for adults and adolescents with depression, as well as bedwetting in children. Imipramine pamoate is only approved to treat depression in adults ages 17 and up."

Answered by AI

Is imipramine used for anxiety?

"Imipramine is a drug that is used to treat depression, anxiety, and panic disorder. It belongs to a class of drugs called tricyclic antidepressants. It is often used to treat bedwetting in children, even though it is not clear how it prevents bedwetting."

Answered by AI

Clinical Trials for Imipramine Pamoate

Image of McLean Hospital in Belmont, United States.

D-Cycloserine + TMS for Mental Health

18+
All Sexes
Belmont, MA

This study is testing whether combining a rapid form of transcranial magnetic stimulation (TMS), an oral medication called d-cycloserine (DCS), and therapy can improve brain flexibility and emotional control in adults experiencing moderate-to-severe depression, anxiety, or trauma symptoms. TMS is a non-invasive treatment that uses gentle magnetic pulses to stimulate specific areas of the brain. In this phase of the study, all participants receive active accelerated TMS (delivering multiple brief sessions in a single day) along with DCS, a medication that helps enhance brain learning and plasticity. Participants will be randomly assigned to have TMS directed at one of two brain targets: a region called the precuneus (identified using personalized brain scans) or the dorsolateral prefrontal cortex (a standard area for mood treatment). Afterward, participants are randomly assigned to complete three weeks of either therapist-led talk therapy (a modified Unified Protocol) or self-guided educational videos and readings. The main goals are to determine which brain stimulation target works best and to see whether therapist-led therapy leads to more lasting symptom relief and brain changes compared to self-guided education.

Phase 2
Waitlist Available

McLean Hospital

Image of Wahwala Iyohlogya/Peaceful Means in Pine Ridge, United States.

Lakota Family Acceptance Program for Relationship or Family Issues

Any Age
All Sexes
Pine Ridge, SD

Although research documents the concerning rates of mental and behavioral health problems (e.g., substance use/initiation) among Indigenous LGBTQ2S+ youth, there is very little known about how to prevent these deleterious issues that devastate Indigenous communities. The study will include \~40 families (Lakota LGBTQ2S+ youth and caregivers) in Rapid City, SD (20 families (10 FAP; 10 wait-list control) and on the nearby Pine Ridge Indian Reservation (10 FAP; 10 wait-list control). Following the baseline survey, families will be randomly assigned to the treatment or wait-list control. Participants will complete an immediate post-test and 6-month follow-up survey to test the hypotheses that FAP will lead to changes in targets, specifically increases in caregiver accepting behaviors, youth and caregiver connection to Lakota culture, family bonding, and youth future orientation and decreases in caregiver rejecting behaviors, caregiver harsh parenting, and youth internalized homo/bi/transphobia compared to the control condition. The researchers will also examine the hypotheses that there will be reductions in deleterious primary outcomes (depressive symptoms, anxiety symptoms, suicidality) and secondary outcomes (alcohol and drug use/initiation and dating and sexual violence victimization and perpetration) among youth in the treatment conditions compared to the control condition. Additionally, the researchers will assess the acceptability and feasibility of the FAP via program observations, post-session surveys, and exit interviews.

Waitlist Available
Has No Placebo

Wahwala Iyohlogya/Peaceful Means (+1 Sites)

Katie Edwards, PhD

Image of Summit Hyperbarics and Wellness in Boise, United States.

Hyperbaric Oxygen Therapy for Traumatic Brain Injury

18 - 75
All Sexes
Boise, ID

The goal of this study is to examine changes in cognitive functioning and post-concussive symptoms following hyperbaric oxygen therapy (HBOT) in current and former first responders with a history of traumatic brain injury. The main questions it aims to answer are: 1. Do cognitive functioning and post-concussive symptoms change after 40 HBOT sessions? 2. Do symptoms of PTSD, depression, and anxiety, or quality of life, change after treatment? Approximately 54 participants will: * Complete medical and behavioral health screening. * Complete cognitive tests and questionnaires before and after treatment. * Receive 40 HBOT sessions at 2.0 atmospheres absolute (ATA), twice daily with at least four hours between sessions. All participants will receive HBOT. There is no comparison group, so the study cannot determine whether HBOT caused any observed changes.

Phase 2
Recruiting

Summit Hyperbarics and Wellness

Steve Wyman, MD

Image of Attune Neurosciences, Inc. in San Francisco, United States.

Focused Ultrasound for Depression, Anxiety, and OCD

22 - 80
All Sexes
San Francisco, CA

This is a double-blind, within-participant crossover, multi-site dose-finding study evaluating the safety, feasibility, and preliminary efficacy of repeated low-intensity focused ultrasound (LIFU) stimulation using the ATTN201 device across seven candidate deep-brain targets in adults with subsyndromal-to-moderate depression, anxiety, or obsessive-compulsive disorder. Every session delivers active ATTN201 stimulation; there is no sham or placebo condition. Participants and the on-site study staff who deliver stimulation and administer the clinical scales are blinded to the brain target and to the stimulation parameters assigned for each session by a constrained Bayesian optimization algorithm.

Waitlist Available
Has No Placebo

Attune Neurosciences, Inc.

Attune Neurosciences Inc

Have you considered Imipramine Pamoate clinical trials?

We made a collection of clinical trials featuring Imipramine Pamoate, we think they might fit your search criteria.
Go to Trials
Image of Steven A. Cohen Military Family Clinics at Red Rock, Colorado Springs in Colorado Springs, United States.

Parenting-STAIR Modular for PTSD and Depression

18+
All Sexes
Colorado Springs, CO

The goal of this clinical trial is to learn if a family-based treatment called Parenting-STAIR-Modular (PSTAIR-M) can help military parents recover from trauma, strengthen emotion regulation skills, and improve parent-child relationships. Participants will be trauma-exposed active-duty Service Members (SM) or their spouses who screen positive for PSTD and/or depression, and one identified child (ages 2-10). The main questions it aims to answer are: 1) Does PSTAIR-M reduce parental PTSD and depression symptoms, lower parenting stress, and improve child behavior compared to treatment-as-usual?; and 2) Is PSTAIR-M feasible and acceptable when delivered to military families stationed overseas? Researchers will compare PSTAIR-M to treatment-as-usual (TAU) to see if PSTAIR-M leads to greater improvements in parental PTSD, depression, parenting stress, emotion regulation, child maltreatment risk, and child behavior than usual care. Participants will: 1) attend 12-16 weekly, 1-hour online treatment sessions with their assigned clinicians, 2) complete three 1-hour online assessments administered by research staff, 3) engage with their child in three 15-30-minute online, observed play sessions, 4) have assessments and observed play sessions audio and video recorded.

Waitlist Available
Has No Placebo

Steven A. Cohen Military Family Clinics at Red Rock, Colorado Springs (+3 Sites)

Kathrine S Sullivan, PhD

Image of Massachusetts General Hospital, 55 Fruit Street, Yawkey 6A in Boston, United States.

Methylphenidate for ADHD and Cannabis Use Disorder

16 - 26
All Sexes
Boston, MA

The goal of this clinical trial is to look at how delayed-release, extended-release methylphenidate (Jornay PM), an FDA-approved medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD), works to treat ADHD symptoms in adolescents and young adults (ages 16-26) with ADHD and Cannabis Use Disorder. Researchers will compare delayed-release, extended-release methylphenidate to a placebo (a look-alike substance that contains no drug). Participants will be assigned to take either delayed-release, extended-release methylphenidate or a placebo every night over 12 weeks. Throughout the study, participants will provide urine samples and complete questionnaires about their ADHD symptoms, cannabis use, and other substance use.

Phase 4
Waitlist Available

Massachusetts General Hospital, 55 Fruit Street, Yawkey 6A

Collegium Pharmaceutical, Inc.

Image of Medical University of South Carolina in Charleston, United States.

CHW Support for Post-Traumatic Stress Disorder

18+
All Sexes
Charleston, SC

This pilot study will evaluate the feasibility, acceptability, and preliminary effectiveness of the Trauma Resilience and Recovery Program Plus (TRRP+), a Community Health Worker-enhanced intervention designed to improve behavioral health engagement and recovery among adult trauma survivors with unmet social needs. One hundred adult trauma patients admitted to the Medical University of South Carolina (MUSC) Level I Adult Trauma Center who screen positive for risk of posttraumatic stress disorder (PTSD) or depression and report at least one unmet social need will receive TRRP+ services. Participants will complete assessments at baseline, 1 month, and 3 months after enrollment. The study will also examine implementation barriers and facilitators to support future dissemination and scale-up of the intervention.

Waitlist Available
Has No Placebo

Medical University of South Carolina

Theresa Skojec, PhD

Image of Tactical Mind Research Coalition in Tampa, United States.

Non-Drug Treatments for Anxiety Disorder

18 - 70
All Sexes
Tampa, FL

RESYNC-BH is a research study evaluating a personalized, non-drug brain-and-body treatment approach for adults with ongoing behavioral health symptoms such as depression, anxiety, trauma-related symptoms, sleep problems, attention difficulties, or substance-use concerns. Rather than assigning treatment solely according to psychiatric diagnosis, treatment approaches are selected based on symptoms, physiologic measures, and clinical presentation. Treatment may include noninvasive neuromodulation, sensory stimulation, regulated breathing, and AIP-informed integrative psychotherapy. The study will evaluate whether personalized treatment approaches produce rapid and sustained improvements in behavioral health symptoms and functioning, and whether treatment response is accompanied by measurable changes in neurophysiologic, autonomic, cognitive, inflammatory, and behavioral measures. The study hypothesis is that meaningful clinical improvement is associated with measurable changes across brain, body, cognitive, and behavioral signals, and that early changes in these measures may help characterize treatment response and its durability. The long-term goal is to develop more objective and personalized methods for monitoring behavioral health treatment response.

Waitlist Available
Has No Placebo

Tactical Mind Research Coalition

Brian Pinkston, MD, MPH

Have you considered Imipramine Pamoate clinical trials?

We made a collection of clinical trials featuring Imipramine Pamoate, we think they might fit your search criteria.
Go to Trials
Image of Online Therapy Unit in Regina, Canada.

'Things You Do' Program for Depression and Anxiety

18+
All Sexes
Regina, Canada

Research shows that the single lesson 'Things You Do' Intervention is effective in increasing engagement in everyday healthy actions. However, no research has examined whether its effectiveness is enhanced by incorporating personalized feedback on participants' current level of engagement in healthy actions. In this randomized controlled trial, clients will be randomly assigned to either receive or not receive personalized feedback informing them of their level of engagement in healthy actions over the previous week and encouraging them to participate in more healthy activities. The investigators will examine whether this feedback increases engagement in healthy actions and enhances the effectiveness of the 'Things You Do' Intervention as assessed through changes in primary outcomes.

Recruiting
Has No Placebo

Online Therapy Unit

Heather Hadjistavropoulos, PhD

Image of University of Pennsylvania in Philadelphia, United States.

Transcranial Magnetic Stimulation for Depression

18 - 65
All Sexes
Philadelphia, PA

The goal of this clinical trial is to learn how transcranial magnetic stimulation (TMS) affects brain circuits involving the subgenual anterior cingulate cortex (sgACC) in adults with depression. The main questions it aims to answer are: * Can brain responses in the sgACC before treatment predict improvement in depressive symptoms following TMS? * Does a 6-week course of active TMS, compared with sham TMS, change brain responses in the sgACC? * Are changes in sgACC responses during treatment associated with changes in depressive symptoms? Researchers will compare active TMS with sham TMS to evaluate changes in the targeted brain circuit and depressive symptoms. Participants will: * Receive active or sham TMS every weekday for 6 weeks * Undergo MRI scans with TMS before, during, and after the 6-week intervention to measure brain responses to stimulation * Complete clinical assessments, questionnaires, and cognitive testing * Complete follow-up assessments after the intervention

Phase < 1
Waitlist Available

University of Pennsylvania

Image of University of Chicago in Chicago, United States.

Virtual Group Therapy for Inflammatory Bowel Disease

18+
All Sexes
Chicago, IL

This study is being done to better understand the complex relationship between mental health and Inflammatory Bowel Disease (IBD), with a particular focus on symptoms of depression and anxiety. While depression and anxiety have traditionally been viewed as reactions to the burden of living with IBD, new research suggests that the biological factors involved in IBD may also contribute directly to these mental health challenges. This study aims to evaluate whether a virtual, group-based psychological treatment is both acceptable and feasible for patients with IBD who experience significant depression and/or anxiety. Researchers will also evaluate participants' depression, generalized anxiety, and associated psychosocial factors (poor sleep quality, GI-specific anxiety, fatigue) before, during, and after treatment. Finally, researchers will evaluate disease severity as it relates to mental health status by comparing it to symptoms, biochemical disease and tryptophan metabolites from blood and stool samples. People who agree to join the study will be asked to attend three in-person visits and 10 virtual group psychotherapy sessions over 11 weeks. Participants will be asked to complete questionnaires, give stool and blood samples, and the research team will collect information about participations from medical records.

Waitlist Available
Has No Placebo

University of Chicago

Alyse Bedell, PhD, CST

Image of California State University, San Bernardino in San Bernardino, United States.

Binaural Beats for ADHD

18 - 55
All Sexes
San Bernardino, CA

This study is conducted entirely in person at California State University, San Bernardino. Participation requires 12 campus visits over six weeks. Remote participation is not available, and travel expenses are not reimbursed. Participants who complete all study visits will receive a gift valued at $25. This study will evaluate the feasibility and potential effects of a six-week, music-based binaural beats stimulation program in adults with attention-deficit/hyperactivity disorder (ADHD). Forty adults with ADHD will be randomly assigned to either a binaural beat stimulation group or a control group. Both groups will attend 12 supervised listening sessions over six weeks and listen to similar music for 20 minutes per session; however, only the intervention group's music will contain embedded binaural beats. Cognitive assessments will be completed before and after the intervention to evaluate changes in attention and memory. Session attendance and participant retention will also be examined to assess the feasibility and acceptability of the program.

Recruiting
Online Trial

California State University, San Bernardino

Have you considered Imipramine Pamoate clinical trials?

We made a collection of clinical trials featuring Imipramine Pamoate, we think they might fit your search criteria.
Go to Trials